Novartis adds bispecific antibodies to its growing immuno-oncology portfolio
Novartis announced a collaboration and licensing agreement with Xencor for development of bispecific antibodies for treating cancer. Novartis receives the right to develop four additional bispecific antibodies and up to ten additional biotherapeutic programs across the Novartis R&D portfolio. June 28, 2016